| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ASTHMA |
1 Université de Montréal, Montréal, Québec, Canada
2 Hôpital du Sacré-C
ur de Montréal, Montréal, Québec, Canada
3 Endowment Pharmaceutical Chair AstraZeneca in Respiratory Health
4 Hôpital Ste-Justine, Montréal, Québec, Canada
Correspondence to:
Correspondence to:
Professeur agrégé L Blais
Université de Montréal, Faculté de pharmacie, CP 6128, succursale Centre-ville, Montréal, Québec, Canada H3C 3J7; lucie.blais{at}umontreal.ca
Aim: To investigate whether the maternal use of different doses of inhaled corticosteroids (ICSs) during the first trimester of pregnancy for the treatment of asthma increases the risk of congenital malformations in the offspring.
Methods: From the linkage of three administrative Canadian databases, a cohort of 4561 pregnancies from women with asthma who delivered between 1990 and 2000 was reconstructed. A two-stage sampling cohort design was used to acquire additional data from the woman’s medical chart. Cases of congenital malformation were identified from the medical services database or the hospital database. Using refill patterns of medications, the average daily dose of ICSs used during the first trimester was calculated and categorised as follows: 0, 1–500, 500–1000 and >1000 µg/day in beclomethasone–chlorofluorocarbon equivalent. A Generalized Estimation Equation model was used to estimate the adjusted odds ratio of congenital malformation as a function of ICS daily dose. All analyses were performed for all malformations and major malformations separately.
Results: Within the cohort 418 babies were identified with a congenital malformation (9.2%), 278 of which had a major malformation. About 40% of women used ICSs during the first trimester, but only 5.3% of women used >500 µg/day. The adjusted odds ratio (95% CI) for all malformations associated with the use of ICSs during the first trimester was: 0.77 (0.53 to 1.13) for 1–500, 0.41 (0.19 to 0.92) for 501–1000 and 1.00 (0.42 to 2.36) for >1000 µg/day. The corresponding figures for major malformations were 0.90 (0.64 to 1.24), 0.56 (0.22 to 1.43) and 1.67 (0.56 to 5.03).
Conclusion: This study adds evidence to the safety of ICSs for the treatment of asthma during pregnancy, with regard to the likelihood of congenital malformation.
Abbreviations: CFC, chlorofluorocarbon; GEE, Generalized Estimation Equation; ICS, inhaled corticosteroid; ISQ, Institut de la statistique du Québec; RAMQ, Régie de l’assurance-maladie du Québec
This article has been cited by other articles:
|
|
 |
|
  M. Cazzola and M. G. Matera Treatment of asthma during pregnancy: more solid evidence needed Thorax, November 1, 2008; 63(11): 944 - 945. [Full Text] [PDF]
|
|
|
|
|
|
L J Tata, S A Lewis, T M McKeever, C J P Smith, P Doyle, L Smeeth, J E Gibson, and R B Hubbard Effect of maternal asthma, exacerbations and asthma medication use on congenital malformations in offspring: a UK population-based study Thorax, November 1, 2008; 63(11): 981 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ramos, M. St-Andre, E. Rey, D. Oraichi, and A. Berard Duration of antidepressant use during pregnancy and risk of major congenital malformations The British Journal of Psychiatry, May 1, 2008; 192(5): 344 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lehman Evidently... Evid. Based Med., October 1, 2007; 12(5): 135 - 135. [Full Text] [PDF]
|
|
|
|
|
|
Other articles noted Evid. Based Med., October 1, 2007; 12(5): 159 - 160. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
